Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes

Similar documents
Introduction. Risk factors of PVD 5/8/2017

Complications of Diabetes: Screening and Prevention

What s New in the Management of Peripheral Arterial Disease

Joshua A. Beckman, MD. Brigham and Women s Hospital

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Case Study: Chris Arden. Peripheral Arterial Disease

Peripheral Arterial Disease Management A Practical Guide for Internists. EFIM Vascular Working Group

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu

Diabetes Mellitus: A Cardiovascular Disease

Introduction to Peripheral Arterial Disease. Stacey Clegg, MD Interventional Cardiology August

Objectives. Abdominal Aortic Aneuryms 11/16/2017. The Vascular Patient: Diagnosis and Conservative Treatment

HIHIM Clinical Cocepts for Managers 7/31/2009. Fernando Vega, MD 1

New indicators to be added to the NICE menu for the QOF and amendments to existing indicators

How would you manage Ms. Gold

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015

CVD risk assessment using risk scores in primary and secondary prevention

Complications of Diabetes: Screening and Prevention. Dr Martin McIntyre Consultant Physician Royal Alexandra Hospital Paisley

03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE

Peripheral Arterial Disease Extremity

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

ESM 1. Survey questionnaire sent to French GPs. Correct answers are in bold. Part 2: Clinical cases: (Good answer are in bold) Clinical Case 1:

Stroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital

Role of ABI in Detecting and Quantifying Peripheral Arterial Disease

Is there a role for a Vascular Specialist Podiatrist in the diabetes MDfT / FPT?

A new era in the treatment of peripheral artery disease (PAD)?

OUTPATIENT DEPARTMENT

STATINS FOR PAD Long - term prognosis

National Vascular Registry

Peripheral Vascular Disease Patient Awareness

LLL Session - Nutrition support in diabetes and dyslipidemia. Dyslipidemia: targeting the management of cardiovascular risk factors. M.

NON-CORONARY ARTERIAL DISEASE

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

The Struggle to Manage Stroke, Aneurysm and PAD

Atherosclerotic Disease Risk Score

surtout qui n est PAS à risque?

- Lecture - Recommandations ESC : messages importants P. MEYER (Saint Laurent du Var) - Controverse - Qui doit faire l'angioplastie périphérique?

Richard Grocott Mason

The aching, cramping pain of

Long-Term Complications of Diabetes Mellitus Macrovascular Complication

The Clinical Unmet need in the patient with Diabetes and ACS

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

USWR 23: Outcome Measure: Non Invasive Arterial Assessment of patients with lower extremity wounds or ulcers for determination of healing potential

Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s

Peripheral Arterial Disease (PAD): Presentation, Diagnosis, and Treatment

Practical Point in Diabetic Foot Care 3-4 July 2017

Learning About. Peripheral Artery Disease

Preventive Cardiology Scientific evidence

14/15 Threshold 15/16 Points 15/16. Points. Retired Replaced by NM82/AF007. Replacement NO CHANGE

Ulster, Ireland. Submitted: 21 June 2009; Revised: 24 January 2010; Published: 13 September 2010 Petrazzuoli F, Soler JK, Buono N, Dobbs F

LIST OF ABBREVIATIONS

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology

HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM

Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines

7 th Munich Vascular Conference

Peripheral Vascular Disease

WHI Form Report of Cardiovascular Outcome Ver (For items 1-11, each question specifies mark one or mark all that apply.

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Guidelines on cardiovascular risk assessment and management

Predictors of restenosis and cardiovascular events in patients undergoing percutaneous angioplasty for subclavian/innominate artery stenosis

The TNT Trial Is It Time to Shift Our Goals in Clinical

ACC NY Cardiovascular Symposium

CVD Prevention, Who to Consider

SUMMARY OF CHANGES TO QOF 2014/15 - ENGLAND CLINICAL

Learning Objectives for Rotations in Vascular Surgery Year 3 Basic Clerkship

Commissioning for value focus pack

Cardiovascular Update for Primary Care Providers. Peripheral Vascular Disease October 4 th 2014 Roberto A. Corpus Jr., MD

National Vascular Registry

Early Identification of PAD: Evidence to Refute USPSTF Position on Screening

Cardiovascular Disease in CLI Patients

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

Session : Why do stroke patients need a cardiologist? PREVALENCE OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CEREBRAL INFARCTION

Coronary Heart Disease in Women Go Red for Women

Claudication Treatment Comparative Effectiveness: 6 Month Outcomes from the CLEVER Study

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

SAVE LIMBS SAVE LIVES!

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease

Cardiovascular Complications of Diabetes

Treatment to reduce cardiovascular risk: multifactorial management

Intercepting PAD. Playbook for Cardiovascular Care 2018 February 24, Jonathan D Woody, MD, FACS. University Surgical Vascular

The contractor establishes and maintains a register of patients with AF

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES

The Diabetic Foot Screen and Management Foundation Series of Modules for Primary Care

Jordan M. Garrison, MD FACS, FASMBS

The Diabetes Link to Heart Disease

Atherosclerosis. Atherosclerosis happens when the blood vessels

National Clinical Conference 2018 Baltimore, MD

SUMMARY OF CHANGES TO QOF 2017/18 - ENGLAND CLINICAL

17/18 Threshold 18/19 Points 18/19. Points NO CHANGE NO CHANGE NO CHANGE

Coronary heart disease and stroke

SUE MATTHEWS, 1 PAM SMITH, 1 PAUL CHADWICK, 2 VINCE SMYTH 3

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

What s new in cardiovascular disease risk assessment and management for primary care clinicians

C L I N I C A L S E Q U E L A E O F A T H E R O T H R O M B O S I S : P E R I P H E R A L A R T E R Y D I S E A S E

SOURCE EMBOLI (mural thrombi ) FROM THE HEART : -LEFT ATRIUM -LEFT VENTRICLE -AORTIC VALVE -MITRAL VALVE

EDUCATION. Peripheral Artery Disease

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary

Summary of 2011/12 QOF indicator changes, points and thresholds

Lipid Management 2013 Statin Benefit Groups

Transcription:

Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes Ashok Handa Reader in Surgery and Consultant Surgeon Nuffield Department of Surgery University of Oxford

Introduction Vascular disease is a major cause of mortality in the West Accounts for >40% of deaths in the UK Atherosclerosis is the underlying cause

Background Common 4.5% 55-74 yrs symptomatic claudication 20% elderly men

Co-existence of Coronary, Cerebral and Peripheral Vascular Disease Prevalence of vascular disease in a population 62 years of age and over Coronary artery disease Peripheral vascular disease 21% 9% 5% 8% 8% 3% 9% Cerebrovascular disease

Athero-thrombosis affects many vascular beds Ischaemic stroke Transient ischaemic attack Myocardial infarction Angina: Stable Unstable Peripheral arterial disease: Intermittent claudication Rest pain Gangrene Necrosis Adapted from: Drouet L. Cerebrovasc Dis 2002; 13(Suppl 1): 1 6 Renovascular disease Diabetes (type 2) Often considered vascular equivalent to a non-diabetic patient with previous MI 2 Adapted from Haffner SM et al. N Engl J Med 1998;339:229-234

Clinical Presentation Acutely with threatened limb (6 P s) Chronically with IC, rest pain, ulceration or gangrene Associated coronary artery disease Associated cerebral arterial disease

The six P s Pain Pallor Paralysis Parasthesia Pulseless Perishing cold

Clinical Assessment History of presenting complaint Risk factors Coronary symptoms Cerebral symptoms

Risk Factors Tobacco Smoking Hypertension Hypercholesterolaem ia Diabetes Mellitus Family History

Implication for patients Degree of Handicap? Extent of Disability? Quality of Life Lifestyle Limitation

Investigation Laboratory ECG ABPI Lifestyle limitation

Objective Assessment Treadmill Corridor Walking Test 6 Minute Walking Test Quality of Life assessment Activity restriction list!!

Further Investigation Depends of impact to patient Duplex scan Angiography CT angiography MRA Cardiac assessment

Outcome Dormandy 1991 Leng 1996 Patients 1,966 116 Follow up 1 year 5 years Reconstruction 5 % 10% Amputation 1.6% 5%

One event leads to another Original Event = Stroke MI Risk 2-3 x greater risk 2 * Stroke Risk 9 x greater risk 3 Original Event = MI MI Risk 5-7 x greater risk 1+ Stroke Risk 3-4 x greater risk 2++ Original Condition = PAD MI Risk 4 x greater risk 4 ** Stroke Risk 2-3 x greater risk 3++ Diabetes (type 2) Because of the increased risk associated with diabetes, it should be considered a cardiovascular risk equivalent to a non-diabetic patient with previous MI Data is increased risk vs general population (%) *Includes angina and sudden death. Sudden death defined as death documented within 1 hour and attributed to coronary heart disease (CHD) **Includes only fatal heart attack and other CHD death; does not include non-fatal heart attack, + Includes death ++Includes TIA 1. Adult Treatment Panel II. Circulation 1994; 89:1333 63. 2. Kannel WB. J Cardiovasc Risk 1994; 1: 333 9. 3. Wilterdink JI, Easton JD. Arch Neurol1992; 49: 857 63. 4. Criqui MH et al. N Engl J Med 1992; 326: 381 6.

Patients with Type 2 diabetes are a high cardiovascular risk group 7-yr incidence of cardiovascular events (%) MI (18.8%) Stroke (7.2%) CV* Death (15.9%) 20 15 10 5 MI (20.2%) Stroke (10.3%) CV* Death (15.4%) Prior MI (no diabetes) 0 Type 2 diabetes (no prior MI) *CV = cardiovascular 1. Adapted from Haffner SM et al. N Engl J Med 1998;339:229-234

Events and inpatient rates in 1 year Number of disease locations 0* 1 2 3 1 in 20 risk in first year 1 in 10 risk in first year 1 in 5 risk in first year 1 in 4 risk in first year 0 5 10 15 20 25 30 % of patients having an event * 1. Adapted from Steg PG et al. JAMA 2007; 297: 1197-1206 PAOD doubles risk

Typical UK General Practice with Disease in Two Vascular Beds Approximately 1.3 million patients with MVD in UK 2* 87% of 1.3 million = 1.1m patients approximately 36,016 UK Full Time Equivalent GPs 1 31 patients with disease in 2 beds per GP 87% of MVD patients have disease in 2 beds 2 Patients with 2 vascular locations have a risk of CV death/mi/stroke or hospitalisation within 12 months 3 CAD+CVD = 20% CAD+PAD = 23% CVD+PAD = 22% * Derived from Key demographic statistics RCGP Information sheet. Available at http://www.rcgp.org.uk/pdf/iss_fact_06_keystats.pdf Last accessed 30 January 2008 Din Link data on file 3. Steg GL et al. JAMA 2007;297(11):1197-1206

Mortality Survival 5 yrs 70% (90% controls) 10 yrs 50% 15 yrs 30%

Risk factors for progression of IC Odds Ratio Smoking 3 Diabetes 2 Hypertension 1.4 Age 1.2 Male gender 1.7 Hypercholesterolaemia no studies

Treatment Options Risk Factor Modification Exercise Angioplasty (PTA) PTA plus Stent Endarterectomy Bypass Surgery

Risk factor Modification Smoking cessation BP control Lipid lowering Glycaemic control Antiplatelet agent Weight reduction Exercise programme

Managing Diabetes Guideline: JBS2 1 SIGN (2001) 2 HbA 1c < 6.5 7.5% ~7% Blood pressure < 130/80 mmhg < 140/80 mmhg Total cholesterol < 4 mmol/l <5 mmol/l LDL cholesterol < 2 mmol/l NONE Use low-dose aspirin QOF targets (41 pts) 3 : HbA 1c < 7.5% Blood Pressure < 145/85 mmhg Total cholesterol < 5 mmol/l Records of: - BP - BMI - Total cholesterol - HbA 1c - Neuropathy testing, micro-albuminuria testing QOF threshold: 40-50% 40-60% 40-70% 40-90% 40-90% 40-90% 40-90% 40-90% 1. Joint British Societies Guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005; 91 (Suppl V) 2. SIGN 55. Management of diabetes, 2001 3. http://www.bma.org.uk/ap.nsf/content/qof06~summclinical (last accessed 28/02/07)

Presentations in patients with diabetes Incidental on screening Co-existing disease in other beds Claudication Atrophic changes in feet Ulceration Foot infections Rest Pain

Assessments in patients with diabetes History Examination Look between toes Look at heels Check for sensation Palpate pulses ABPI with caution

Special needs in patients with diabetes Aggressive risk factor modification Good footcare and regular self examination Access to podiatry Early referral for vascular review Beware Infections rapid deterioration potential

Any questions? Or maybe clear as mud?